Sosenko Piscitello Anastasia, Nilsson Ann-Sofie, Hawgood Michael, Sayyid Abid H, Dionellis Vasilis S, Giglio Giovanni, Urién Bruno, Bajgain Pratikiran, Ntallis Sotirios G, Bartek Jiri, Halazonetis Thanos D, Lemmens Bennie
Department of Molecular and Cellular Biology, University of Geneva, Geneva, Switzerland.
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden.
Nat Commun. 2025 Sep 12;16(1):8268. doi: 10.1038/s41467-025-63669-8.
Cyclin-dependent kinases (CDKs) coordinate DNA replication and cell division, and play key roles in tissue homeostasis, genome stability and cancer development. The first step in replication is origin licensing, when minichromosome maintenance (MCM) helicases are loaded onto DNA by CDC6, CDT1 and the origin recognition complex (ORC). In yeast, origin licensing starts when CDK activity plummets in G1 phase, reinforcing the view that CDKs inhibit licensing. Here we show that, in human cells, CDK4/6 activity promotes origin licensing. By combining rapid protein degradation and time-resolved EdU-sequencing, we find that CDK4/6 activity acts epistatically to CDC6 and CDT1 in G1 phase and counteracts RB pocket proteins to promote origin licensing. Therapeutic CDK4/6 inhibitors block MCM and ORC6 loading, which we exploit to trigger mitosis with unreplicated DNA in p53-deficient cells. The CDK4/6-RB axis thus links replication licensing to proliferation, which has implications for human cell fate control and cancer therapy design.
细胞周期蛋白依赖性激酶(CDK)协调DNA复制和细胞分裂,并在组织稳态、基因组稳定性和癌症发展中发挥关键作用。复制的第一步是起始许可,此时微小染色体维持(MCM)解旋酶由CDC6、CDT1和起始识别复合物(ORC)加载到DNA上。在酵母中,当CDK活性在G1期骤降时起始许可开始,这强化了CDK抑制许可的观点。在此我们表明,在人类细胞中,CDK4/6活性促进起始许可。通过结合快速蛋白质降解和时间分辨的EdU测序,我们发现CDK4/6活性在G1期对CDC6和CDT1起上位作用,并对抗RB口袋蛋白以促进起始许可。治疗性CDK4/6抑制剂阻断MCM和ORC6加载,我们利用这一点在p53缺陷细胞中用未复制的DNA触发有丝分裂。因此,CDK4/6-RB轴将复制许可与增殖联系起来,这对人类细胞命运控制和癌症治疗设计具有重要意义。